
CAS 1413431-07-8
:Fórmula:C24H28N2O3
InChI:InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)/i4D3,5D3,6D3
Chave InChI:PURKAOJPTOLRMP-ASMGOKTBSA-N
SMILES:[2H]C([2H])([2H])C(C1=C(C=C(C(=C1)C(C)(C)C)NC(=O)C2=CNC3=CC=CC=C3C2=O)O)(C([2H])([2H])[2H])C([2H])([2H])[2H]
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Foram encontrados 6 produtos.
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
N-(2-(tert-Butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
CAS:N-(2-(tert-Butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideFórmula:C24H19D9N2O3Pureza:99.83%Peso molecular:401.55Ivacaftor (4-tertbutyl-d9) (Major)
CAS:Produto ControladoFórmula:C24H19D9N2O3Cor e Forma:NeatPeso molecular:401.55Ivacaftor (4-tertbutyl-d9) (major)
CAS:Ivacaftor is a drug substance with the molecular formula C17H20Cl2O3, a monocarboxylic acid amide. Ivacaftor is indicated as a treatment for cystic fibrosis (CF) in patients age 12 years and older who have one of the following mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or R117C. Ivacaftor binds to and activates the CFTR protein by increasing its stability and function. The carboxyl terminal domain of CFTR is required for interaction with ivacaftor. Ivacaftor also potentiates the activity of chromenes such as ivacaftor (4-tertbutyl-d9) and other cftr potentiators such as VX-770. These compounds are being studied in cancer treatment because they may be able toFórmula:C24H28N2O3Pureza:Min. 95%Peso molecular:401.5 g/molIvacaftor-D9
CAS:Ivacaftor-D9 is a deuterated compound of ivacaftor used for isotope tracing. Ivacaftor is an effective, orally administered CFTR modulator, cystic fibrosis.Fórmula:C24H19D9N2O3Pureza:99.13%Cor e Forma:White SolidPeso molecular:401.55





